 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...30313233343536373839404142» |
- goserelin acetate / Generic mfg., anastrozole / Generic mfg.
Enrollment change, Metastases: S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 1, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
N=56 --> 0
- anastrozole / Generic mfg.
Enrollment open: ANASILPRA: Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome (clinicaltrials.gov) - Dec 9, 2012
P=N/A, N=40, Recruiting, Sponsor: Assistance Publique - H
N=56 --> 0 Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD)
Enrollment open, Metastases: Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy (clinicaltrials.gov) - Dec 5, 2012
P=N/A, N=14, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Soltamox (tamoxifen citrate) / Jazz
Enrollment closed, Surgery: Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (clinicaltrials.gov) - Dec 2, 2012
P3, N=11248, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- anastrozole / Generic mfg., risedronate / Generic mfg.
Biomarker, Trial withdrawal: Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS (clinicaltrials.gov) - Nov 27, 2012
P3, N=0, Withdrawn, Sponsor: International Breast Cancer Study Group
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- anastrozole / Generic mfg., risedronate / Generic mfg.
Biomarker, Enrollment change: Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS (clinicaltrials.gov) - Nov 27, 2012
P3, N=0, Withdrawn, Sponsor: International Breast Cancer Study Group
Recruiting --> Withdrawn N=1000 --> 0
- | sapitinib (AZD8931) / AstraZeneca
Trial termination, Combination therapy, Metastases: MINT: Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer (clinicaltrials.gov) - Nov 15, 2012
P2, N=482, Terminated, Sponsor: AstraZeneca
N=1000 --> 0 Active, not recruiting --> Terminated; Futility
- Avastin (bevacizumab) / Roche
Trial termination, Metastases: Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 12, 2012
P2, N=3, Terminated, Sponsor: University of Pittsburgh
Active, not recruiting --> Terminated; Futility Recruiting --> Terminated; Poor enrollment/suspended to accrual; will close per AstraZeneca request
- Avastin (bevacizumab) / Roche
Enrollment change, Metastases: Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 12, 2012
P2, N=3, Terminated, Sponsor: University of Pittsburgh
Recruiting --> Terminated; Poor enrollment/suspended to accrual; will close per AstraZeneca request N=100 --> 3
- Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - Nov 6, 2012
P2, N=29, Recruiting, Sponsor: Washington University School of Medicine
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment change: Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer (clinicaltrials.gov) - Nov 5, 2012
P1, N=50, Recruiting, Sponsor: Medivation, Inc.
N=100 --> 3 N=27 --> 50
- Biomarker, Enrollment open: MIRHO: Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer (clinicaltrials.gov) - Nov 5, 2012
P4, N=39, Recruiting, Sponsor: Institut Claudius Regaud
N=27 --> 50 Not yet recruiting --> Recruiting
- | rhGH-Emisphere (somatropin oral, oral recombinant human growth hormone) / Novo Nordisk, Ligand, Genotropin (somatropin) / Pfizer, Nutropin AQ (somatropin) / Ipsen, Roche
Enrollment closed, Combination therapy: ThrasherAI: Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature (clinicaltrials.gov) - Oct 30, 2012
P3, N=77, Active, not recruiting, Sponsor: Nemours Children's Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- anastrozole / Generic mfg.
Enrollment open: Anastrozole in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 15, 2012
P2, N=18, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- anastrozole / Generic mfg.
Enrollment change: FABrC: Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics (clinicaltrials.gov) - Oct 1, 2012
P0, N=28, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting N=100 --> 28
- | Zokinvy (lonafarnib) / Eiger
Trial completion, Metastases: Anastrozole With or Without Lonafarnib in Treating Postmenopausal Women With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer (clinicaltrials.gov) - Sep 12, 2012
P2, N=0, Completed, Sponsor: Jonsson Comprehensive Cancer Center
N=100 --> 28 Recruiting --> Completed
- |||||| anastrozole / Generic mfg., fulvestrant / Generic mfg.
Enrollment open, Metastases: FALCON: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (clinicaltrials.gov) - Sep 12, 2012
P3, N=605, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Not yet recruiting --> Recruiting
- anastrozole / Generic mfg.
Enrollment change: CEP-1 Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men (clinicaltrials.gov) - Sep 11, 2012
P2, N=31, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting N=24 --> 31
- ketoconazole / Generic mfg., anastrozole / Generic mfg., dutasteride capsule / Generic mfg.
Trial completion: ITT4 Intratesticular Hormonal Milieu in Man (ITT4) (clinicaltrials.gov) - Sep 4, 2012
P1/2, N=46, Completed, Sponsor: University of Washington
N=24 --> 31 Recruiting --> Completed
- || everolimus / Generic mfg.
New P3 trial: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Aug 26, 2012
P3, N=3500, Recruiting, Sponsor: Southwest Oncology Group
- anastrozole / Generic mfg., tegafur/uracil / Generic mfg.
Trial suspension, Combination therapy: Neo-ACET BC: Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer (clinicaltrials.gov) - Aug 14, 2012
P2, N=120, Suspended, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Recruiting --> Completed Recruiting --> Suspended
- ||||||| Herceptin (trastuzumab) / Roche
Trial completion: A Study to Evaluate the Efficacy and Safety of Herceptin (clinicaltrials.gov) - Aug 9, 2012
P3, N=208, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended Active, not recruiting --> Completed
- ||||||| anastrozole / Generic mfg., fulvestrant / Generic mfg.
Trial completion, Combination therapy, Monotherapy: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy (clinicaltrials.gov) - Jul 26, 2012
P3, N=514, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- anastrozole / Generic mfg.
Enrollment change, Adverse events: ORACLES: Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects (clinicaltrials.gov) - Jul 19, 2012
P=N/A, N=490, Active, not recruiting, Sponsor: Centre Oscar Lambret
Active, not recruiting --> Completed N=207 --> 490
- anastrozole / Generic mfg., fulvestrant / Generic mfg.
Enrollment closed: NIMFEA: Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P2, N=116, Active, not recruiting, Sponsor: UNICANCER
N=207 --> 490 Recruiting --> Active, not recruiting
- anastrozole / Generic mfg., gefitinib / Generic mfg.
Enrollment change, Combination therapy, Metastases: Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer (clinicaltrials.gov) - Jul 18, 2012
P2, N=71, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting N=108 --> 71
- letrozole / Generic mfg., anastrozole / Generic mfg., gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy (clinicaltrials.gov) - Jul 16, 2012
P2, N=44, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=108 --> 71 Active, not recruiting --> Completed
- ||| Trial initiation date: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy (clinicaltrials.gov) - Jul 5, 2012
P2, N=300, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Initiation date: Feb 2011 --> Aug 2011
- || anastrozole / Generic mfg.
Enrollment change: Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects (clinicaltrials.gov) - Jun 21, 2012
P1, N=58, Completed, Sponsor: AstraZeneca
Initiation date: Feb 2011 --> Aug 2011 N=40 --> 58
- ||| anastrozole / Generic mfg.
Trial completion: Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects (clinicaltrials.gov) - Jun 21, 2012
P1, N=58, Completed, Sponsor: AstraZeneca
N=40 --> 58 Recruiting --> Completed
- Biomarker, New P4 trial: MIRHO: Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer (clinicaltrials.gov) - Jun 4, 2012
P4, N=39, Recruiting, Sponsor: Institut Claudius Regaud
- ||||||| anastrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: ATAC - Arimidex, Tamoxifen Alone or in Combination (clinicaltrials.gov) - Jun 4, 2012
P3, N=9358, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Active, not recruiting --> Completed
- ||| anastrozole / Generic mfg.
Trial completion, HEOR: RADAR II E: Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=1510, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| anastrozole / Generic mfg.
Trial completion: Breast Cancer Tumor Care Observational Programme (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=150, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- leuprolide acetate for depot suspension / Generic mfg., anastrozole / Generic mfg., testosterone gel / Generic mfg.
Trial completion: Regulation of Cortisol Metabolism and Fat Patterning (clinicaltrials.gov) - Jun 3, 2012
P=N/A, N=140, Completed, Sponsor: Oregon Health and Science University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zadaxin (thymalfasin) / SciClone
Trial withdrawal, Combination therapy: Dendritic Cell Based Therapy for Breast Cancer Patients (clinicaltrials.gov) - May 29, 2012
P2, N=0, Withdrawn, Sponsor: Inge Marie Svane
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zadaxin (thymalfasin) / SciClone
Enrollment change, Combination therapy: Dendritic Cell Based Therapy for Breast Cancer Patients (clinicaltrials.gov) - May 29, 2012
P2, N=0, Withdrawn, Sponsor: Inge Marie Svane
Active, not recruiting --> Withdrawn N=100 --> 0
- sapitinib (AZD8931) / AstraZeneca
Enrollment change, Combination therapy, Metastases: MINT: Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer (clinicaltrials.gov) - May 27, 2012
P2, N=482, Terminated, Sponsor: AstraZeneca
N=100 --> 0 N=345 --> 482
- |||||||||| anastrozole / Generic mfg., fulvestrant / Generic mfg.
New P3 trial, Metastases: FALCON: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (clinicaltrials.gov) - May 17, 2012
P3, N=605, Recruiting, Sponsor: AstraZeneca
- capecitabine / Generic mfg.
Trial termination, Metastases: Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer (clinicaltrials.gov) - May 9, 2012
P2/3, N=10, Terminated, Sponsor: The Netherlands Cancer Institute
N=345 --> 482 Recruiting --> Terminated; acrual too slow
- capecitabine / Generic mfg.
Enrollment change, Metastases: Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer (clinicaltrials.gov) - May 9, 2012
P2/3, N=10, Terminated, Sponsor: The Netherlands Cancer Institute
Recruiting --> Terminated; acrual too slow N=128 --> 10
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P1 trial: Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer (clinicaltrials.gov) - May 9, 2012
P1, N=50, Recruiting, Sponsor: Medivation, Inc.
- pazopanib / Generic mfg., anastrozole / Generic mfg.
Trial termination: Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer (clinicaltrials.gov) - May 6, 2012
P2, N=2, Terminated, Sponsor: University of Arizona
N=128 --> 10 Recruiting --> Terminated; Slow accrual
- pazopanib / Generic mfg., anastrozole / Generic mfg.
Enrollment change: Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer (clinicaltrials.gov) - May 6, 2012
P2, N=2, Terminated, Sponsor: University of Arizona
Recruiting --> Terminated; Slow accrual N=50 --> 2
- ||||| anastrozole / Generic mfg., everolimus / Generic mfg., exemestane / Generic mfg.
Enrollment closed, Combination therapy, Metastases: BOLERO-2: Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (clinicaltrials.gov) - May 3, 2012
P3, N=724, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=50 --> 2 Recruiting --> Active, not recruiting
- anastrozole / Generic mfg.
Trial completion: Anastrozole Administration in Elderly Hypogonadal Men (clinicaltrials.gov) - May 2, 2012
P2, N=100, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| anastrozole / Generic mfg.
New P1 trial: Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects (clinicaltrials.gov) - Mar 29, 2012
P1, N=58, Completed, Sponsor: AstraZeneca
- anastrozole / Generic mfg., toremifene / Generic mfg.
Trial termination: Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer (clinicaltrials.gov) - Mar 27, 2012
P2, N=240, Terminated, Sponsor: Japan Breast Cancer Research Network
Active, not recruiting --> Completed Recruiting --> Terminated
- tamoxifen / Generic mfg.
New P4 trial: OXYTAM: Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not (clinicaltrials.gov) - Mar 12, 2012
P4, N=29, Completed, Sponsor: Institut Claudius Regaud
- |||| anastrozole / Generic mfg.
Trial completion: Arthralgia During Anastrozole Therapy for Breast Cancer (clinicaltrials.gov) - Mar 12, 2012
P4, N=114, Completed, Sponsor: AstraZeneca
Recruiting --> Terminated Active, not recruiting --> Completed